To include your compound in the COVID-19 Resource Center, submit it here.

Stoking the embers

Ember raises $34M from Third Rock to develop preclinical metabolic programs

Stoking the embers

Ember Therapeutics officially launched last week with a $34 million series A round from Third Rock Ventures to develop a pair of preclinical projects plucked from academia that could result in peripherally acting compounds to treat metabolic disorders, including obesity and

Read the full 436 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers